Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company known for its cystic fibrosis (CF) treatments, is at a critical juncture as it seeks to diversify its portfolio and maintain its ...
Analyst Salveen Richter of Goldman Sachs maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), reducing the price target ...
Vertex (VRTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...
The Food and Drug Administration on Thursday approved Journavx, a non-opioid painkiller that is the first novel pain drug to win government authorization in more than 20 years. Vertex ...
The FDA has approved a new non-opioid prescription medication, Journavx for adults with moderate to severe acute pain.
The first shot taken at Medicaid, likely UnitedHealthcare coverage for Vertex's pain drug, and Optum’s wellness visit ad.
The FDA's approval of the non-addictive painkiller Journavx last week marked a milestone in the field of pain management. Why ...
For the first time in more than 25 years, the U.S. Food and Drug Administration has signed off on a new type of pain reliever ...
The opioid epidemic continues to affect hundreds of thousands of people, but there may be hope for the future with a new, non ...
While it's next to impossible to know how many opioids entered the state illegally in 2023, we do know that just under 1.7 ...
The Food and Drug Administration (FDA) is hoping a newly approved non-opioid pain medication could help save lives. Dr.
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...